Conference
Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer
Abstract
We have shown that adjuvant cyclophosphamide (C), epirubicin (E), 5-FU (F) chemotherapy improves survival compared to CMF in pre-menopausal women with lymph node-positive (NP) breast cancer (NCIC-CTG MA5, JCO,1998). In that study, 5 cases of acute leukemia (AL) were seen among 359 patients receiving CEF, a crude rate of 1.4%. To refine the estimate of risk of AL after E-based chemotherapy, we used a competing risk method (Pepe and Mori, Stat …
Authors
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
Volume
69
Publication Date
December 1, 2001
Conference proceedings
Breast Cancer Research and Treatment
Issue
3
ISSN
0167-6806